LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Kodu・Aktsiate loetelu・Intra-Cellular Therapies Inc

Intra-Cellular Therapies Inc

Suletud

Sektor Tervishoid

73.5 1.62

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

73.3

Max

73.83

Põhinäitajad
By Trading Economics
Sissetulek	-973K -16M
Müük	17M 161M
Aktsiakasum	-0.16
Kasumimarginaal	-10.05
Töötajad	610
EBITDA	-6.8M -28M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+31.13 upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	31. okt 2024

Turustatistika
By TradingEconomics
Turukapital	-335M 7.1B
Eelmine avamishind	71.88
Eelmine sulgemishind	73.5

Uudiste sentiment

By Acuity

34%

66%

290 / 365 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

72.26 / 74.48 Toetus ja vastupanu

Intra-Cellular Therapies Inc Graafik

Seotud uudised

7. sept 2024, 09:30 UTC

Peamised uudised

Jobs Slowdown Frustrates Investors Who Wanted Certainty on the Fed -- WSJ

7. sept 2024, 08:20 UTC

Market Talk

Financial Services Roundup: Market Talk

6. sept 2024, 22:41 UTC

Market Talk

KinderCare and StandardAero File for IPOs -- Market Talk

6. sept 2024, 21:18 UTC

Peamised uudised

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- Update

6. sept 2024, 21:05 UTC

Peamised uudised

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 4th Update

6. sept 2024, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6. sept 2024, 20:39 UTC

Tulu

Update: NIO Stock Caught an Upgrade. Shares Rose. -- Barrons.com

6. sept 2024, 20:35 UTC

Peamised uudised

Stocks Extend Ugly Week of Losses Amid Economic Uncertainty -- WSJ

6. sept 2024, 20:34 UTC

Peamised uudised

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 3rd Update

6. sept 2024, 20:11 UTC

Peamised uudised

Stock Indexes Close Lower After Mixed Jobs Report -- WSJ

6. sept 2024, 19:51 UTC

Peamised uudised

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- WSJ

6. sept 2024, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Hold Gains -- Market Talk

6. sept 2024, 19:14 UTC

Market Talk

Oil Futures Extend Losses on Demand Concerns -- Market Talk

6. sept 2024, 19:01 UTC

Market Talk

Gold Slips on Prevailing Uncertainty -- Market Talk

6. sept 2024, 18:27 UTC

Peamised uudised

JPMorgan Plans to Report Customers Who Exploited TikTok 'Glitch' to Authorities -- WSJ

6. sept 2024, 18:25 UTC

Market Talk

Broadcom Growth Views Conservative Amid AI Investments -- Market Talk

6. sept 2024, 18:15 UTC

Peamised uudised

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- Update

6. sept 2024, 18:12 UTC

Peamised uudised

Nasdaq Falls 2.5%, Leads Losses After Mixed Jobs Report -- WSJ

6. sept 2024, 17:44 UTC

Market Talk

Labor Costs Represent Diminishing Risk To Canada CPI, CIBC's Shenfeld Says -- Market Talk

6. sept 2024, 17:30 UTC

Market Talk

U.S Oil Rig Count Unchanged at 483 -- Market Talk

6. sept 2024, 17:30 UTC

Peamised uudised

Boeing's Starliner Is Returning to Earth Without Its Crew -- WSJ

6. sept 2024, 17:27 UTC

Peamised uudised

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- WSJ

6. sept 2024, 17:00 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6. sept 2024, 17:00 UTC

Market Talk

Mexican Inflation Seen Easing in August -- Market Talk

6. sept 2024, 16:36 UTC

Market Talk

Oil Futures Fall as U.S. Jobs Report Sinks In -- Market Talk

6. sept 2024, 16:35 UTC

Tulu

Kuumad aktsiad

Stocks to Watch Friday: Broadcom, Nvidia, UiPath, Smith & Wesson -- WSJ

6. sept 2024, 16:33 UTC

Omandamised, ülevõtmised, äriostud

Salesforce Stock Is on Pace for Longest Losing Streak Since 2008. An Acquisition Isn't Helping. -- Barrons.com

6. sept 2024, 16:20 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

6. sept 2024, 16:20 UTC

Tulu

Oracle Profit, Revenue Set to Rise in 1Q -- Earnings Preview

6. sept 2024, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Intra-Cellular Therapies Inc Prognoos

Hinnasiht

By TipRanks

31.13% tõus

12 kuu keskmine prognoos

Keskmine 96.43 USD 31.13%

Kõrge 130 USD

Madal 74 USD

Põhineb 15 Wall Streeti analüütiku instrumendi Intra-Cellular Therapies Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

15 ratings

Osta

Hoia

Müü

Põhineb 15 analüütiku instrumendi Intra-Cellular Therapies Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

72.26 / 74.48Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There are no events.

Sentiment

By Acuity

290 / 365 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Intra-Cellular Therapies Inc

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company that is focused on the discovery, clinical development, and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company offers CAPLYTA for the treatment of schizophrenia as is typical for antipsychotics. Its lumateperone bipolar depression clinical program consists of three monotherapy studies and one adjunctive study. The Company also initiated its third monotherapy Phase III study, Study 403, evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder.